GlassScriptPhysician profile
Sarah Endlein
NPI 1215689047
$7,350.45
in general payments reported to CMS, 2019-2025
30 companies · $3,547 in 2025
The $3,547 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,171 · 2024: $2,632 · 2025: $3,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,338 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,338.30 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.56 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,107.81 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $544.43 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $515.26 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $447.14 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $440.87 | 2023-2025 | Auvelity |
| Lundbeck LLC | $356.11 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $344.79 | 2024-2025 | Qelbree |
| Corium, LLC | $339.46 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $274.44 | 2024 | |
| Janssen Pharmaceuticals, INC | $264.12 | 2023-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $241.76 | 2024-2025 | Trintellix |
| Noven Therapeutics, LLC | $179.51 | 2024-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $165.32 | 2024-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $161.25 | 2025 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $134.27 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $131.43 | 2023 | Mounjaro, Trulicity, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $103.50 | 2023-2025 | Cobenfy, Eliquis |
| Pfizer INC. | $86.44 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.65 | 2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $52.63 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $45.75 | 2023 | Ozempic, Rybelsus, Wegovy |
| Sage Therapeutics, LLC | $35.39 | 2025 | Zurzuvae |
| Luye Pharma (USA) LTD. | $34.04 | 2025 | Erzofri Extended-Release |
| Abbott Laboratories | $29.01 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $28.59 | 2023 | Breztri, Farxiga |
| Indivior INC. | $27.32 | 2023 | Perseris |
| Dexcom, INC. | $22.78 | 2023 | Dexcom G6 Transmitter |
| Owp Pharmaceuticals, INC. | $20.63 | 2024 | Subvenite |
| Bayer Healthcare Pharmaceuticals INC. | $13.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Endlein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.